Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Molecular and functional characterization of cynomolgus monkey IgG subclasses.

Jacobsen FW, Padaki R, Morris AE, Aldrich TL, Armitage RJ, Allen MJ, Lavallee JC, Arora T.

J Immunol. 2011 Jan 1;186(1):341-9. doi: 10.4049/jimmunol.1001685. Epub 2010 Dec 3.

2.

CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells.

Stewart R, Wei W, Challa A, Armitage RJ, Arrand JR, Rowe M, Young LS, Eliopoulos A, Gordon J.

J Immunol. 2007 Sep 1;179(5):2705-12.

3.

Deciphering CD30 ligand biology and its role in humoral immunity.

Kennedy MK, Willis CR, Armitage RJ.

Immunology. 2006 Jun;118(2):143-52. Review.

4.
5.

Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells.

Challa A, Eliopoulos AG, Holder MJ, Burguete AS, Pound JD, Chamba A, Grafton G, Armitage RJ, Gregory CD, Martinez-Valdez H, Young L, Gordon J.

Blood. 2002 May 1;99(9):3411-8.

6.

Modelling the human immune response: can mice be trusted? Commentary.

Gordon CJ, Grafton G, Wood PM, Larché M, Armitage RJ.

Curr Opin Pharmacol. 2001 Aug;1(4):431-5. Review.

PMID:
11710744
7.

Phase I study of recombinant human CD40 ligand in cancer patients.

Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG.

J Clin Oncol. 2001 Jul 1;19(13):3280-7.

PMID:
11432896
8.

CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin.

Gordon J, Challa A, Levens JM, Gregory CD, Williams JM, Armitage RJ, Cook JP, Roberts LM, Lord JM.

Cell Death Differ. 2000 Sep;7(9):785-94.

9.

CD154.

Armitage RJ.

J Biol Regul Homeost Agents. 2000 Apr-Jun;14(2):145-7. No abstract available.

PMID:
10841293
10.

CD153.

Armitage RJ.

J Biol Regul Homeost Agents. 2000 Apr-Jun;14(2):142-4. No abstract available.

PMID:
10841292
11.

Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48.

Kubin MZ, Parshley DL, Din W, Waugh JY, Davis-Smith T, Smith CA, Macduff BM, Armitage RJ, Chin W, Cassiano L, Borges L, Petersen M, Trinchieri G, Goodwin RG.

Eur J Immunol. 1999 Nov;29(11):3466-77.

13.

Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells.

Pound JD, Challa A, Holder MJ, Armitage RJ, Dower SK, Fanslow WC, Kikutani H, Paulie S, Gregory CD, Gordon J.

Int Immunol. 1999 Jan;11(1):11-20.

PMID:
10050669
14.

Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).

Morris AE, Remmele RL Jr, Klinke R, Macduff BM, Fanslow WC, Armitage RJ.

J Biol Chem. 1999 Jan 1;274(1):418-23.

15.

Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand.

Baker MP, Eliopoulos AG, Young LS, Armitage RJ, Gregory CD, Gordon J.

Blood. 1998 Oct 15;92(8):2830-43.

16.

The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor.

Strockbine LD, Cohen JI, Farrah T, Lyman SD, Wagener F, DuBose RF, Armitage RJ, Spriggs MK.

J Virol. 1998 May;72(5):4015-21.

17.

Molecular characterization of the human interleukin (IL)-17 receptor.

Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, VandenBos T, Zappone JD, Painter SL, Armitage RJ.

Cytokine. 1997 Nov;9(11):794-800.

PMID:
9367539
18.

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.

Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M.

Br J Haematol. 1998 Jan;100(1):135-41.

PMID:
9450802
19.

Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation.

Milner AE, Grand RJ, Vaughan AT, Armitage RJ, Gregory CD.

Oncogene. 1997 Oct 9;15(15):1815-22.

20.
21.
22.

CD48 delivers an accessory signal for CD40-mediated activation of human B cells.

Klyushnenkova EN, Li L, Armitage RJ, Choi YS.

Cell Immunol. 1996 Nov 25;174(1):90-8.

PMID:
8929458
23.

CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator.

Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS.

Oncogene. 1996 Nov 21;13(10):2243-54.

PMID:
8950992
24.

The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation.

Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, Ulrich D, Alderson MR, Müllberg J, Cohen JI.

J Virol. 1996 Aug;70(8):5557-63.

26.

Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein.

Wang H, Grand RJ, Milner AE, Armitage RJ, Gordon J, Gregory CD.

Oncogene. 1996 Jul 18;13(2):373-9.

PMID:
8710376
27.

Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation.

Yao Z, Maraskovsky E, Spriggs MK, Cohen JI, Armitage RJ, Alderson MR.

J Immunol. 1996 May 1;156(9):3260-6.

PMID:
8617948
28.

Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines.

MacDonald I, Wang H, Grand R, Armitage RJ, Fanslow WC, Gregory CD, Gordon J.

Blood. 1996 Feb 1;87(3):1147-54.

29.

Human IL-17: a novel cytokine derived from T cells.

Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ.

J Immunol. 1995 Dec 15;155(12):5483-6.

PMID:
7499828
30.

CD40 cross-linking inhibits specific antibody production by human B cells.

Callard RE, Herbert J, Smith SH, Armitage RJ, Costelloe KE.

Int Immunol. 1995 Nov;7(11):1809-15.

PMID:
8580079
31.

Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.

Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ, Fanslow WC, Rager HC, Taub DD, Ruscetti FW, et al.

Blood. 1995 Sep 1;86(5):1946-53.

32.
33.

Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.

Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK.

Eur J Immunol. 1995 Jul;25(7):2083-9.

PMID:
7621881
34.

B-cell stimulation.

Armitage RJ, Alderson MR.

Curr Opin Immunol. 1995 Apr;7(2):243-7. Review.

PMID:
7546384
35.

IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation.

Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH.

J Immunol. 1995 Jan 15;154(2):483-90.

PMID:
7814861
36.

Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15.

Matthews DJ, Clark PA, Herbert J, Morgan G, Armitage RJ, Kinnon C, Minty A, Grabstein KH, Caput D, Ferrara P, et al.

Blood. 1995 Jan 1;85(1):38-42.

37.

Humoral immune responses in CD40 ligand-deficient mice.

Renshaw BR, Fanslow WC 3rd, Armitage RJ, Campbell KA, Liggitt D, Wright B, Davison BL, Maliszewski CR.

J Exp Med. 1994 Nov 1;180(5):1889-900.

38.

The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization.

Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, Baker E, Sutherland GR, Poindexter K, Birks C, et al.

J Immunol. 1994 Oct 15;153(8):3574-83.

PMID:
7930580
39.

CD40 ligand (CD40L) expression and B cell function in agammaglobulinemia with normal or elevated levels of IgM (HIM). Comparison of X-linked, autosomal recessive, and non-X-linked forms of the disease, and obligate carriers.

Callard RE, Smith SH, Herbert J, Morgan G, Padayachee M, Lederman S, Chess L, Kroczek RA, Fanslow WC, Armitage RJ.

J Immunol. 1994 Oct 1;153(7):3295-306.

PMID:
7916370
40.

Structural characteristics of CD40 ligand that determine biological function.

Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ.

Semin Immunol. 1994 Oct;6(5):267-78. Review.

PMID:
7532457
41.

Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.

Gruss HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Barcos M, Strockbine L, Armitage RJ, Dower SK.

Blood. 1994 Oct 1;84(7):2305-14.

42.

Molecular and biological characterization of human 4-1BB and its ligand.

Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, Falk B, Roux E, Baker E, Sutherland GR, Din WS.

Eur J Immunol. 1994 Sep;24(9):2219-27.

PMID:
8088337
43.
44.

Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction.

Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA.

J Immunol. 1994 Jun 15;152(12):5643-52.

PMID:
7515910
45.

Tumor necrosis factor receptor superfamily members and their ligands.

Armitage RJ.

Curr Opin Immunol. 1994 Jun;6(3):407-13. Review.

PMID:
7917108
46.

B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors.

Benjamin D, Sharma V, Knobloch TJ, Armitage RJ, Dayton MA, Goodwin RG.

J Immunol. 1994 May 15;152(10):4749-57.

PMID:
8176200
47.

Inhibition of human B-cell lymphoma growth by CD40 stimulation.

Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ.

Blood. 1994 May 15;83(10):2787-94.

48.

Recombinant CD40 ligand exerts potent biologic effects on T cells.

Fanslow WC, Clifford KN, Seaman M, Alderson MR, Spriggs MK, Armitage RJ, Ramsdell F.

J Immunol. 1994 May 1;152(9):4262-9.

PMID:
7908915
49.

Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG.

Blood. 1994 Apr 15;83(8):2045-56.

50.

CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.

Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF.

J Immunol. 1994 Jan 1;152(1):117-28.

PMID:
7504707

Supplemental Content

Loading ...
Support Center